Four-factor prothrombin complex concentrate improves thrombin generation and prothrombin time in patients with bleeding complications related to rivaroxaban: a single-center pilot trial

BACKGROUND: Direct oral anticoagulants (DOACs) pose a great challenge for physicians in life-threatening bleeding events. The aim of this study was to test the efficacy of reversing the DOAC rivaroxaban using four-factor PCC (prothrombin complex concentrate), a non-specific reversing agent. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Schenk, Bettina, Goerke, Stephanie, Beer, Ronny, Helbok, Raimund, Fries, Dietmar, Bachler, Mirjam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5763793/
https://www.ncbi.nlm.nih.gov/pubmed/29344007
http://dx.doi.org/10.1186/s12959-017-0158-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5763793/
https://www.ncbi.nlm.nih.gov/pubmed/29344007
http://dx.doi.org/10.1186/s12959-017-0158-9

Ejemplares similares